Literature DB >> 15527694

Pheochromocytoma: diagnosis and management update.

William M Manger1, Graeme Eisenhofer.   

Abstract

Pheochromocytoma is a rare but extremely treacherous neuroendocrine tumor causing manifestations by secreting catecholamines into the circulation. It is usually fatal if unrecognized. Manifestations can mimic many diseases and cause erroneous diagnoses. Approximately 15% are malignant, 18% extra-adrenal, and 20% familial. Plasma or urinary metanephrines are approximately 98% sensitive for detecting pheochromocytomas. They can be localized by MRI and CT; (131)I- and (123)I-metaiodobenzylguanidine (MIBG) are highly specific and 81% to 90% sensitive, respectively. Suspect pheochromocytoma in patients with sustained or paroxysmal hypertension or in normotensives having manifestations of hypercatecholaminemia. Surgical removal is usually curative; chemotherapy and radiotherapy are palliative for malignant pheochromocytomas.

Entities:  

Mesh:

Year:  2004        PMID: 15527694     DOI: 10.1007/s11906-004-0044-2

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  29 in total

1.  Radiofrequency ablation: a novel approach for treatment of metastatic pheochromocytoma.

Authors:  K Pacak; T Fojo; D S Goldstein; G Eisenhofer; M M Walther; W M Linehan; L Bachenheimer; J Abraham; B J Wood
Journal:  J Natl Cancer Inst       Date:  2001-04-18       Impact factor: 13.506

2.  Editorial: In search of pheochromocytomas.

Authors:  William M Manger
Journal:  J Clin Endocrinol Metab       Date:  2003-09       Impact factor: 5.958

3.  [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in begnign and malignant pheochromocytomas.

Authors:  E van der Harst; W W de Herder ; H A Bruining; H J Bonjer; R R de Krijger ; S W Lamberts; A H van de Meiracker ; F Boomsma; T Stijnen; E P Krenning; F T Bosman; D J Kwekkeboom
Journal:  J Clin Endocrinol Metab       Date:  2001-02       Impact factor: 5.958

4.  Biochemical diagnosis of pheochromocytoma: which test is best?

Authors:  Jacques W M Lenders; Karel Pacak; McClellan M Walther; W Marston Linehan; Massimo Mannelli; Peter Friberg; Harry R Keiser; David S Goldstein; Graeme Eisenhofer
Journal:  JAMA       Date:  2002-03-20       Impact factor: 56.272

5.  MR imaging of pheochromocytomas.

Authors:  I J Fink; J W Reinig; A J Dwyer; J L Doppman; W M Linehan; H R Keiser
Journal:  J Comput Assist Tomogr       Date:  1985 May-Jun       Impact factor: 1.826

6.  Phaeochromocytomas discovered during coronial autopsies in Sydney, Melbourne and Auckland.

Authors:  A R McNeil; B H Blok; T D Koelmeyer; M P Burke; J M Hilton
Journal:  Aust N Z J Med       Date:  2000-12

Review 7.  The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients.

Authors:  K C Loh; P A Fitzgerald; K K Matthay; P P Yeo; D C Price
Journal:  J Endocrinol Invest       Date:  1997-12       Impact factor: 4.256

Review 8.  Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma.

Authors:  K Pacak; W M Linehan; G Eisenhofer; M M Walther; D S Goldstein
Journal:  Ann Intern Med       Date:  2001-02-20       Impact factor: 25.391

9.  Benign adrenal lesions mimicking malignancy on MR imaging: report of two cases.

Authors:  M E Baker; C Spritzer; R Blinder; R J Herfkens; G S Leight; N R Dunnick
Journal:  Radiology       Date:  1987-06       Impact factor: 11.105

10.  Scintigraphic localization of pheochromocytoma.

Authors:  J C Sisson; M S Frager; T W Valk; M D Gross; D P Swanson; D M Wieland; M C Tobes; W H Beierwaltes; N W Thompson
Journal:  N Engl J Med       Date:  1981-07-02       Impact factor: 91.245

View more
  19 in total

Review 1.  New roles of carboxypeptidase E in endocrine and neural function and cancer.

Authors:  Niamh X Cawley; William C Wetsel; Saravana R K Murthy; Joshua J Park; Karel Pacak; Y Peng Loh
Journal:  Endocr Rev       Date:  2012-03-07       Impact factor: 19.871

2.  Peptide receptor radionuclide therapy for metastatic paragangliomas.

Authors:  David J Pinato; James R M Black; Ramya Ramaswami; Tricia M Tan; Delali Adjogatse; Rohini Sharma
Journal:  Med Oncol       Date:  2016-04-08       Impact factor: 3.064

3.  Hypertension in pheochromocytoma: characteristics and treatment.

Authors:  Samuel M Zuber; Vitaly Kantorovich; Karel Pacak
Journal:  Endocrinol Metab Clin North Am       Date:  2011-06       Impact factor: 4.741

Review 4.  Neoplasms associated with germline and somatic NF1 gene mutations.

Authors:  Sachin Patil; Ronald S Chamberlain
Journal:  Oncologist       Date:  2012-01-12

5.  Laparoscopic resection of primary adrenal ganglioneuroma: A case report and review of the literature.

Authors:  Yuan Zhou; Qilian Liang; Wen-Ting Ou; Zhou-Yu Li; Qiu-Long Liu
Journal:  Oncol Lett       Date:  2015-03-09       Impact factor: 2.967

6.  Attention Deficit Hyperactivity Disorder in Pediatric Patients with Pheochromocytoma and Paraganglioma.

Authors:  M Batsis; U Dagalakis; C A Stratakis; T Prodanov; G Z Papadakis; K Adams; M Lodish; K Pacak
Journal:  Horm Metab Res       Date:  2016-05-12       Impact factor: 2.936

7.  Postural tachycardia syndrome with asystole on head-up tilt.

Authors:  Amer Alshekhlee; Meziane Guerch; Faisal Ridha; Kevin Mcneeley; Thomas C Chelimsky
Journal:  Clin Auton Res       Date:  2007-10-19       Impact factor: 4.435

Review 8.  [Pheochromocytoma - still a challenge].

Authors:  N Reisch; M K Walz; Z Erlic; H P H Neumann
Journal:  Internist (Berl)       Date:  2009-01       Impact factor: 0.743

Review 9.  Sporadic paraganglioma.

Authors:  James A Lee; Quan-Yang Duh
Journal:  World J Surg       Date:  2008-05       Impact factor: 3.352

10.  Retroperitoneal paraganglioma: a chameleon masquerading as an adrenal pheochromocytoma.

Authors:  K Parmar; A Chandna; S Kumar
Journal:  Ann R Coll Surg Engl       Date:  2018-10-29       Impact factor: 1.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.